FLORIDA INTERNATIONAL UNIVERSITY – 6 Studies
Presenter: Mario De La Rosa, Ph.D.
|
Basic Science/Virology
|
Platelets Mediating Alcohol and HIV Damage
|
Maria-Jose Miguez (PI)
|
Robert Stempel College of Public Health and Social Work
|
To evaluate platelets, platelet associated factors, immune and cognitive function in four groups: hazardous and non-hazardous alcohol consuming HIV-infected subjects and hazardous and non-hazardous alcohol consuming HIV sero-negative subjects
Funded by NIAAA
|
Basic Science/Virology
|
Polydrug Nanocarrier to Treat Opiate Addiction and HIV Disease
|
Madhavan Nair (PI), Zainulabedin Saiyed
|
Herbert Wertheim College of Medicine
|
To use state-of-the-art nanotechnology for HIV drug targeting to brain affected by Neuro-AIDS through the following specific aims: To develop a magnetoliposome based multifunctional nanocarrier bound to CTOP, BDNF and AZTTP
To test the developed formulation in vitro for its ability to transmigrate across BBB. To evaluate the in vivo efficacy of the developed nanocarrier in an HIVE SCID morphine mouse model; Funded by NIDA
|
Basic Science/Virology
|
Mechanisms of Neuro-AIDS by HIV1B and C Clades
|
Madhavan Nair (PI), Robert Malow, Zainulabedin Saiyed
|
Herbert Wertheim College of Medicine
|
To investigate the molecular mechanisms of clade-specific neuronal dysfunctions associated with clade-specific HIV infections, and to suggest novel anti-HIV therapeutic research strategies to alleviate the HIV induced neuronal dysfunctions in HIV infected subjects; Funded by NIDA
|
Basic Science/Virology
|
Cytokines An Underlying Cause Of Health Disparities In Tobacco Related Diseases
|
Maria Jose Míguez-Burbano, MD, PhD (PI)
|
Florida International University
|
The principal tasks of this five-year longitudinal translational study, which builds upon our previous work, are to examine the immunological and behavioral mechanisms underlying health disparities in tobacco related diseases in PLWH and PLWOH. Specifically, we propose to search for disparities in the gene expression and cytokine production patterns. Funding: James and Esther King Florida Health Department
|
Basic Science/Virology
|
NIH NIAAA 1R01AA018095-01 Title: Platelets Mediating Alcohol and HIV Damage
|
Miguez, Malow, Nair
|
Florida International University
|
The first aim of this 5 years longitudinal study is to confirm an inverse relationship between alcohol use and platelet counts and explore putative mediating immune mechanisms. Building on our previous findings and published data, our second aim is to investigate the relationship between platelet counts and levels of platelet associated factors (PAF, BDNF, serotonin) and neuropsychological function in PLWH.
|
Basic Science/Virology
|
NIH NIAAA 1R01AA018095-01 Platelets and the Blood Brain Barrier
|
Miguez, Nair
|
Florida International University
|
The main task of this project is to explore the plausible role of platelets in the disruption of the blood brain barrier among PLWH and identify if factors released from apoptotic platelets may be underpinning the damage
|
VACCINE & GENE THERAPY INSTITUTE – FLORIDA – 7 Studies
Presenters: Rafick Pierre Sékaly, Ph.D. & Lydie Trautmann, Ph.D.
|
Basic Science/Virology
|
Investigating the impact of homeostatic proliferation on HIV persistence
|
Dr. Sekaly, Dr. Chomont, Dr. Cameron, Dr. Wilkinson
|
N/A
|
HIV reservoirs
|
Basic Science/Virology
|
The role of negative regulators of T cell activation in the maintenance of viral latency
|
Dr Chomont, Dr Sekaly
|
N/A
|
HIV reservoirs
|
Basic Science/Virology
|
Identifying the antigen specificity of the latent reservoir: A rationale for the development of vaccine aimed at activating HIV-specific CD4 T cell
|
Dr Chomont
|
|
HIV reservoirs
|
Basic Science/Virology
|
Understanding the first immunological events in acute HIV infection.
|
Dr. Trautmann, Dr Sekaly, Dr MBitikon-Kobo
|
VGTI-FL
|
Acute HIV infection
|
Basic Science/Virology
|
Systems biology approaches to identify innate and adaptive mucosal immune correlates of protection from HIV infection
|
Dr. Trautmann, Dr. MBitikon-Kobo, Dr. Fischl, Dr. Castro and Dr. Pahwa
|
VGTI-FL, University of Miami School of Medicine
|
Mucosal immunity and HIV
|
Basic Science/Virology
|
Screening of small molecules aimed at reactivating HIV from its latent reservoirs
|
Dr Chomont, Dr. Sekaly
|
VGTI and Merck
|
HIV reservoirs
|
Basic Science/Virology
|
Evasion of the innate immune response by HIV-1
|
John Hiscott
|
VGTI Microbiology & Immunology and McGill University
|
Antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I (Solis et al, J. Virol. 85:1224-1236, 2011)
|
Broward Children’s Diagnostic & Treatment Center - 2 Studies
Presented by Ana Puga, M.D.
|
Basic Science/Virology
|
ATN 081: Treatment De-Intensification and Residual HIV-1 in Adolescents and Young Adults (on-going)
|
Ana Puga, MD
|
CFAP Research
|
Residual Viral Load in patients in Highly Active Antiretroviral Therapy (HAART) deintensification
|
Behavioral/Epidemiological
Basic Science/Virology
|
IMPAACT P1085 : Duration of Human Papilloma Virus (HPV) Type-Specific Antibody After Administration of Quadrivalent HPV Vaccine to HIV-1 Infected Children Preciously Enrolled in IMPAACT P1047 (recruiting)
|
Ana Puga, MD
|
CFAP Research
|
Duration of HPV antibodies post-vaccination
|
ClinicalTrials.gov Website Studies – 4 Additional Studies
|
Clinical Trial
Basic Science/Virology
|
Safety and Effectiveness of Raltegravir (MK-0518) in Treatment-Experienced, HIV-Infected Children and Adolescents
|
National Institute of Allergy and Infectious Diseases (NIAID)
Sharon A. Nachman, MD, State University of New York at Stony Brook, Health Science Center;
Andrew Wiznia, MD, Jacobi Medical Center, Albert Einstein College of Medicine
|
Termination from treatment due to suspected drug reaction attributable to the study medication; Grade 3 or 4 adverse events; Pharmacokinetic parameters; HIV viral load; CD4 count and percentage; Genotypic and phenotypic resistance measures
Recruiting: Jacksonville, Miami, Ft. Lauderdale, Tampa
|
Clinical Trial
Basic Science/Virology
|
Pilot Assessment of Lopinavir/Ritonavir and Maraviroc in Experienced Patients
NCT00981318
|
Abbott,
Barry M. Rodwick, M. D. Contact: Barry M. Rodwick, M. D. 727-725-9931 Doc@DrRodwick.com
Contact: Tiffany D. Ross, MA CRC 727-725-9931 Tiffany@DrRodwick.com
|
This is a study to assess the response of lopinavir/ritonavir plus maraviroc (with no nucleoside medications) in HIV patients failing their initial antiviral therapy.
|
Basic Science/Virology
|
Phase 2, Randomized, Placebo-controlled Trial to Evaluate the Safety and Effect on Post-HIV Acquisition Viremia of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by a Multiclade HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Adenovirus Type 5 Neutralizing Antibody Negative, Circumcised Men and Male-to-Female (MTF) Transgender Persons, Who Have Sex With Men
NCT00865566
|
Scott Hammer,
Magdalena Sobieszczyk,
Michael Yin – Columbia University;
Orlando Immunology Center
HVTN CRS - Jeffrey Dinsmore, RN
National Institute of
Allergy and Infectious
Diseases (NIAID),
HIV Vaccine Trials Network
|
The purpose of this study is to determine the safety and efficacy of a VRC DNA/rAd5 vaccine regimen in healthy, circumcised men and male-to-female (MTF) transgender persons who have sex with men.
|
Clinical Trial
Basic Science/Virology
|
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
NCT01165203
|
Contact: GSKClinicalSupportHD@gsk.com
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
|
This observer-blind study will evaluate the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational Herpes Zoster (HZ) vaccine GSK1437173A in Human Immunodeficiency Virus (HIV) infected subjects, firstly enrolling subjects treated with antiretroviral therapy (ART) and with high CD4 T cell counts, and subsequently ART-treated subjects with low CD4 T cell counts, and ART-naïve subjects with high CD4 T cell counts. This Protocol Posting has been updated following Amendment 1 of the Protocol, August 2010. The impacted section is exclusion criteria.
|
Yüklə 1.25 Mb.